brilliant News ...:) This acquisition has the potential to...

brilliant News ...

This acquisition has the potential to catapult up - side for Virax shareholders.
It also means that in the next 12 months we expect to be driving five clinical trials, under two
separate IND applications with two of the most advanced trials funded by US government authorities.
“TCN - P or triciribine phosphate monohydrate is a small molecule that blocks
the AKT growth promoting pathway that leads to cancer.
AKT is the most frequently mutated pathway in cancer and thus plays a key role in m
any cancers including those being currently pursued ( breast, ovarian and leukaemia ) as well as
a potential treatment for other cancer s in the future.
High AKT expression is associated with a poor outlook, resistance to chemotherapy and
shortened patient survival time. In animal studies TCNn -Phas been shown to strongly suppress the
growth of high AKT expressing tumours and to overcome resistance to
commonly used chemotherapeutic drugs,
a key feature of the TCN
-
P drug.
Already more than 100 patients have been dosed with TCN
-
P in extensive trials carried out at
highly regarded US cancer centres including the
Lee
Moffitt Cancer Center in Florida,
MD
An
derson in Texas
and the Memorial Sloan Kettering Cancer Cent
e
r in New York.
D
ata from a
completed
Phase 1 study
of TCN
-
P
in hematologic
cancers (primarily
Acute
Myeloid
Leukemia
or AML
)
carried out
at MD Anderson
and Lee Moffitt Cancer
Centers
has

3
www.virax.com.au
VIRAX HOLDINGS LIMITED
shown
encouraging
anti
-
tumo
u
r activity.
A further
Phase 1b
study will be undertaken at the
Moffitt Cancer Cent
e
r
early in 2015
to maximi
s
e traction in the treatment of
AML
,
an
aggressive
form of cancer
that is expected to become more prevalent with
aging
populat
io
n
s